[Featured Stock] GI Innovation Rises on Start of 100% Complete Remission Anticancer Drug Trial in Multiple Myeloma Model

GI Innovation is showing strong performance. This is attributed to news that patient enrollment has begun for the Phase 1/2a clinical trial of a metabolic immuno-oncology drug candidate that achieved a 100% complete remission rate in a multiple myeloma model.

As of 9:17 AM on the 6th, GI Innovation is trading at 17,730 KRW, up 6.49% compared to the previous day.

According to industry sources, GI Innovation started patient enrollment for the Phase 1/2a clinical trial of its 4th-generation metabolic immuno-oncology drug candidate 'GI-108' on this day. GI-108 is a metabolic immuno-oncology drug candidate that inhibits cancer cell metabolism. It was selected in 2022 as a non-clinical development project under the National New Drug Development Project 'New Drug R&D Ecosystem Establishment Research' by the Korea Drug Development Fund (KDDF).

GI-108 is a first-in-class bispecific fusion antibody protein that combines a CD73 antibody with an IL-2 mutant to overcome the insufficient efficacy of CD73 antibodies. GI-108 demonstrated strong anti-cancer activity in various preclinical models of 'cold tumors' (tumors resistant to immuno-oncology drugs).

GI Innovation explained that in a human triple-negative breast cancer model, GI-108 monotherapy showed superior anti-cancer activity compared to Keytruda, a 3rd-generation immuno-oncology drug with global sales of 43 trillion KRW, which is the highest-selling drug in its class.

Notably, in a multiple myeloma model, a 100% complete remission rate was observed with tumor disappearance in the body at the early stage of combination therapy with CAR-T (chimeric antigen receptor immune cells) treatment.

This content was produced with the assistance of AI translation services.